CLAIMS

1. The use of a therapeutically effective amount of cenicriviroc or a salt or solvate thereof in the manufacture of a medicament for treating peritonitis in a subject in need thereof.

2. The use of claim 1, wherein the peritonitis is infected or non-infected.

3. The use of claim 1 or claim 2, wherein the cenicriviroc or a salt or solvate thereof is formulated as a pharmaceutical composition comprising cenicriviroc or a salt or solvate thereof and fumaric acid.

4. The use of claim 1, wherein the peritonitis is associated with a perforation of the gastrointestinal tract.

5. The use of claim 1, wherein the peritonitis is associated with leakage of fluid into the peritoneum.

6. The use of claim 1, wherein the peritonitis is associated with a foreign body.

7. The use of a therapeutically effective amount of cenicriviroc or a salt or solvate thereof in the manufacture of a medicament for treating acute liver injury in a subject in need thereof.

8. The use of claim 7, wherein the acute liver injury is alcohol-induced, acetaminophen-induced, toxin-induced, and/or chemical-induced liver injury.

9. The use of any of the preceding claims, wherein the cenicriviroc or a salt or solvate thereof is formulated as a pharmaceutical composition comprising cenicriviroc or a salt or solvate thereof and fumaric acid.

10. The use of any of the preceding claims, wherein the cenicriviroc or salt or solvate thereof is formulated as an oral composition.

11. The use of any of the preceding claims, wherein the cenicriviroc or salt or solvate thereof is to be administered once per day or twice per day.

12. The use of any of the preceding claims, wherein the cenicriviroc or salt or solvate thereof is to be co-administered with one or more additional active agents or treatments.

13. The use of claim 12, wherein the one or more additional active agents or treatments are one or more antibiotic, glucocorticoid, corticosteroid, Pentoxyfylline, phosphodiesterase inhibitor, anti-TNFα agent, and anti-oxidants.

14. The use of claim 13, wherein the one or more antibiotics is selected from the group consisting of penicillins, cephalosporins, macrolides, fluoroquinolones, sulphonamides, tetracyclines, and aminoglysocides or a combination thereof.

15. The use of claim 12, wherein the one or more additional active agents or treatments is n-acetylcysteine (Acetylcysteine; NAC).

16. The use of claim 15, wherein the NAC is to be administered intravenously.

17. The use of claim 15, wherein the NAC is to be administered orally.